Fig. 4.

Antiviral mechanism of action of the two FDA-approved oral drugs under the emergency use authorization (EUA) for the treatment of COVID-19 patients (A) Paxlovid which inhibits the 3CLpro and (B) Molnupiravir which inserts mutations into the viral genome during replication.